Jens Gempt1, Eric Soehngen2, Stefan Förster3, Yu-Mi Ryang4, Jürgen Schlegel5, Claus Zimmer6, Bernhard Meyer4, Florian Ringel4, Astrid E Grams7, Annette Förschler6. 1. Neurochirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675 München, Germany. Electronic address: jens.gempt@lrz.tum.de. 2. Abteilung für Neuroradiologie, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675 München, Germany; Abteilung für Neuropathologie des Instituts für Allgemeine Pathologie und Pathologische Anatomie, Technische Universität München, Ismaninger Str. 22, 81675 München, Germany. 3. Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675 München, Germany. 4. Neurochirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675 München, Germany. 5. Abteilung für Neuropathologie des Instituts für Allgemeine Pathologie und Pathologische Anatomie, Technische Universität München, Ismaninger Str. 22, 81675 München, Germany. 6. Abteilung für Neuroradiologie, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675 München, Germany. 7. Abteilung für Neuroradiologie, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675 München, Germany; Universitätsklinik für Neuroradiologie, Department Radiologie, Medizinische Universität Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria.
Abstract
INTRODUCTION: Concerning the preoperative clinical diagnostic work-up of glioma patients, tumor heterogeneity challenges the oncological therapy. The current study assesses the performance of a multimodal imaging approach to differentiate between areas in malignant gliomas and to investigate the extent to which such a combinatorial imaging approach might predict the underlying histology. METHODS: Prior to surgical resection, patients harboring intracranial gliomas underwent MRIs (MR-S, PWI) and (18)F-FET-PETs. Intratumoral and peritumoral biopsy targets were defined, by MRI only, by FET-PET only, and by MRI and FET-PET combined, and biopsied prior to surgical resection and which then received separate histopathological examinations. RESULTS: In total, 38 tissue samples were acquired (seven glioblastomas, one anaplastic astrocytoma, one anaplastic oligoastrocytoma, one diffuse astrocytoma, and one oligoastrocytoma) and underwent histopathological analysis. The highest mean values of Mib1 and CD31 were found in the target point "T' defined by MRI and FET-PET combined. A significant correlation between NAA/Cr and PET tracer uptake (-0.845, p<0.05) as well as Cho/Cr ratio and cell density (0.742, p<0.05) and NAA/Cr ratio and MIB-1 (-0761, p<0.05) was disclosed for this target point, though not for target points defined by MRI and FET-PET alone. CONCLUSION: Multimodal-imaging-guided stereotactic biopsy correlated more with histological malignancy indices, such as cell density and MIB-1 labeling, than targets that were based solely on the highest amino acid uptake or contrast enhancement on MRI. The results of our study indicate that a combined PET-MR multimodal imaging approach bears potential benefits in detecting glioma heterogeneity.
INTRODUCTION: Concerning the preoperative clinical diagnostic work-up of gliomapatients, tumor heterogeneity challenges the oncological therapy. The current study assesses the performance of a multimodal imaging approach to differentiate between areas in malignant gliomas and to investigate the extent to which such a combinatorial imaging approach might predict the underlying histology. METHODS: Prior to surgical resection, patients harboring intracranial gliomas underwent MRIs (MR-S, PWI) and (18)F-FET-PETs. Intratumoral and peritumoral biopsy targets were defined, by MRI only, by FET-PET only, and by MRI and FET-PET combined, and biopsied prior to surgical resection and which then received separate histopathological examinations. RESULTS: In total, 38 tissue samples were acquired (seven glioblastomas, one anaplastic astrocytoma, one anaplastic oligoastrocytoma, one diffuse astrocytoma, and one oligoastrocytoma) and underwent histopathological analysis. The highest mean values of Mib1 and CD31 were found in the target point "T' defined by MRI and FET-PET combined. A significant correlation between NAA/Cr and PET tracer uptake (-0.845, p<0.05) as well as Cho/Cr ratio and cell density (0.742, p<0.05) and NAA/Cr ratio and MIB-1 (-0761, p<0.05) was disclosed for this target point, though not for target points defined by MRI and FET-PET alone. CONCLUSION: Multimodal-imaging-guided stereotactic biopsy correlated more with histological malignancy indices, such as cell density and MIB-1 labeling, than targets that were based solely on the highest amino acid uptake or contrast enhancement on MRI. The results of our study indicate that a combined PET-MR multimodal imaging approach bears potential benefits in detecting glioma heterogeneity.
Authors: Shanshan Jiang; Charles G Eberhart; Yi Zhang; Hye-Young Heo; Zhibo Wen; Lindsay Blair; Huamin Qin; Michael Lim; Alfredo Quinones-Hinojosa; Jon D Weingart; Peter B Barker; Martin G Pomper; John Laterra; Peter C M van Zijl; Jaishri O Blakeley; Jinyuan Zhou Journal: Eur J Cancer Date: 2017-07-10 Impact factor: 9.162
Authors: C Badve; A Yu; S Dastmalchian; M Rogers; D Ma; Y Jiang; S Margevicius; S Pahwa; Z Lu; M Schluchter; J Sunshine; M Griswold; A Sloan; V Gulani Journal: AJNR Am J Neuroradiol Date: 2016-12-29 Impact factor: 3.825
Authors: Vincent Dunet; Anastasia Pomoni; Andreas Hottinger; Marie Nicod-Lalonde; John O Prior Journal: Neuro Oncol Date: 2015-08-04 Impact factor: 12.300
Authors: Lisa Maria Walchhofer; Ruth Steiger; Andreas Rietzler; Johannes Kerschbaumer; Christian Franz Freyschlag; Günther Stockhammer; Elke Ruth Gizewski; Astrid Ellen Grams Journal: Cancers (Basel) Date: 2021-05-26 Impact factor: 6.639